Design Therapeutics, Inc. DSGN Total debt

Total debt at other companies

ALN

Alnylam PharmaceuticalsALNY

$256.43M-5.2%

Intellia TherapeuticsNTLA

$73.41M-28.4%

CRISPR TherapeuticsCRSP

$787.64M+259%

Dyne Therapeutics, Inc.DYN

$168.68M+623%

CytomX TherapeuticsCTMX

$5.7M-17.2%

Taysha Gene Therapies, Inc.TSHA

$68.55M+11.2%

FAQ

What is Design Therapeutics, Inc.'s total debt?

Design Therapeutics, Inc. (DSGN) reported total debt of $2.73M in Q1 2026.

How has Design Therapeutics, Inc.'s total debt changed year-over-year?

Design Therapeutics, Inc.'s total debt increased by 27.7% year-over-year, from $2.14M to $2.73M.

What is the long-term trend for Design Therapeutics, Inc.'s total debt?

Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s total debt has grown at a -19.4% compound annual growth rate (CAGR), from $3.63M to $1.54M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.